ClinicalTrials.gg
RecruitingNCT05764850METYDIAUpdated Mar 13, 2023

Mechanisms of Type 1 Diabetes Endophenotypes

An observational study in Type 1 Diabetes Mellitus and Genetic Predisposition to Disease, sponsored by Pediatric Clinical Research Platform. Recruiting at 1 site in Switzerland. Open to participants aged 0 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-13.

Sponsored by Pediatric Clinical Research Platform · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
150
Ages
0 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland — 9 open to participants now, 10 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Switzerland.

Planned enrollment
7th of 18
150 · median 73
Started
2023
with 6 others
Observational
18 of 70
4 open now
Registered
60th of 70
by date

Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, this one is the 7th largest by planned enrollment of the 18 observational ones that give a count, is one of 7 that started in 2023, is one of 18 observational ones, and was the 60th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

9 of the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 0 Years to 25 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, or all of them as a file.
02

Study summary

The goal of this observational study consists of performing cluster analysis to decipher underlying disease mechanisms of type 1 diabetes in children and young adults.

To this end, we will combine clinical, laboratory, genetic, transcriptomic, and metabolomic datasets of an extensively phenotyped cohort of children and young adults with type 1 diabetes. We will also assess the risk for cardiovascular diseases in this most vulnerable diabetes cohort.

03

Conditions studied

  • Type 1 Diabetes Mellitus
  • Genetic Predisposition to Disease

Keywords

  • Type 1 diabetes mellitus
  • Children
  • Adolescent
  • Young adult
  • Genetic
  • Transcriptomic
  • Metabolomic
  • Lipidomic
  • Genetic risk score
04

Who can participate

Ages eligible
0 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Children, adolescents, and young adults followed at the pediatric diabetology unit of the University Hospital of Geneva.

Controls Children, adolescents, and young adults coming for a routine blood sample at University Hospital of Geneva

Eligibility criteria

Inclusion Criteria (Type 1 Diabetic patients):

  • as documented by signature
  • Patient's age: between 0 and 25 years old.
  • Children, adolescents, and young adult patients followed in diabetology.

Exclusion Criteria (Type 1 Diabetic patients):

  • No exclusion criteria

Inclusion Criteria (Controls):

  • Informed consent as documented by signature
  • Patient's age: 25 less than 6 years of age and 25 between 6 and 25 years old.
  • Healthy patient

Exclusion Criteria (Controls):

  • Patient receiving treatment affecting metabolic control (ex: systemic corticoids, beta blocker, immunotherapy etc.)
  • Concomitant disease that may affect the analysis of the results (ex: cancer, active disease requiring treatment)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Case

    100 patients followed in pediatric diabetology at the university hospital of Geneva: a cohort

    Genetic: Genome sequencing

  • Control

    50 control patients

    Genetic: Genome sequencing

Interventions

  • GeneticGenome sequencing

    100 extensively phenotyped pediatric and young adult patients for genotyping, metabolomic and lipidomic analyses. Polygenic risk scores for type 1 diabetes and cardiovascular disease will be performed. For patients older than 6 years who agree to do a second visit (optional), a Mixed Meal Tolerance Test (MMTT: the gold standard for assessing beta cell function) will be done as well as transcriptomic analysis.

    Also known as: Lipidomic, Metabolomic, Transcriptomic, Mixed meal tolerance test

06

What researchers measure

Primary outcomes

  1. Cluster analysis to decipher underlying mechanisms of type 1 diabetes

    We will combine clinical, laboratory, genetic, transcriptomic, and metabolomic datasets of an extensively phenotyped cohort of type 1 diabetes patients (Children and young adults). We will create clinical and genetic correlates with the following clinical parameters: Age at diabetes onset (years), disease duration (years), BMI (kg/m2), diabetes autoantibodies, C-peptide level (pmol/l) and decline over time, HbA1c (%), insulin dose (U/kg/d), ketoacidosis at disease onset (y/n), lipid levels (Total cholesterol, triglycerides, HLD, LDL, Lipoprotein(a)), macro- and microvascular complications, ethnicity, family history for diabetes, associated autoimmune diseases (e.g., autoimmune thyroiditis or celiac disease) and mixed meal tolerance test.

    Time frame: blood sampling and analyses

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Feb 2026, 36 months after the start.

Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 36 months is above that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2023
First posted
Mar 13, 2023
StartActual
Feb 1, 2023
Primary completionEst.
Feb 1, 2026
CompletionEst.
Feb 1, 2026
Last update
Mar 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05764850
Lead sponsor
Pediatric Clinical Research Platform
Collaborators
University Hospital, Geneva, University of Geneva, Switzerland
Responsible party
Sponsor
First posted
Mar 13, 2023
Start date
Feb 1, 2023
Primary completion
Feb 1, 2026 (estimated)
Completion
Feb 1, 2026 (estimated)
Last update
Mar 13, 2023

Study contacts

Valerie VS Schwitzgebel, MD
Contact
valerie.schwitzgebel@unige.ch
+41 22 372 45 90
Fanny FL Iafrate-Luterbacher, MD
Contact
fanny.luterbacher@hcuge.ch
+41 78 603 06 92
Valerie VS Schwitzgebel, MD
principal investigator · University Hospital of Geneva / University of Geneva

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion